In contrast, the application of BLK inhibitors in treating T-cell lymphoma (where BLK was shown as an oncogene (181)) should be used with caution because inhibiting BLK may attenuate cGAS cytosolic retention leading to deficiency in cGAS activation and dampened T-cell recruitment into tumors. The gene discussed is BLK; the disease is T-cell non-Hodgkin lymphoma.